Short Interest in Applied DNA Sciences, Inc. (NASDAQ:APDN) Drops By 5.1%

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 5,030,000 shares, a decline of 5.1% from the December 15th total of 5,300,000 shares. Based on an average daily volume of 6,020,000 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Trading of Applied DNA Sciences

An institutional investor recently bought a new position in Applied DNA Sciences stock. Jane Street Group LLC acquired a new position in Applied DNA Sciences, Inc. (NASDAQ:APDN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 73,396 shares of the technology company’s stock, valued at approximately $48,000. Jane Street Group LLC owned about 0.24% of Applied DNA Sciences at the end of the most recent quarter. 22.22% of the stock is owned by institutional investors and hedge funds.

Applied DNA Sciences Stock Up 0.7 %

NASDAQ:APDN opened at $0.19 on Monday. The company has a fifty day moving average of $0.19 and a 200-day moving average of $0.55. Applied DNA Sciences has a twelve month low of $0.12 and a twelve month high of $14.40. The firm has a market capitalization of $10.01 million, a P/E ratio of -0.03 and a beta of 0.40.

Applied DNA Sciences (NASDAQ:APDN) last issued its earnings results on Tuesday, December 17th. The technology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. Applied DNA Sciences had a negative return on equity of 111.18% and a negative net margin of 203.76%. On average, analysts anticipate that Applied DNA Sciences will post -0.87 EPS for the current fiscal year.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.